FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Aziyo Biologics, Inc. Stock AnalysisComprehensive stock analysis for Aziyo Biologics, Inc. (AZYO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAZYO
AZYO
Aziyo Biologics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AZYO
Home🔹Stocks🔹Aziyo Biologics, Inc.

Aziyo Biologics, Inc.

AZYO•NASDAQ

Aziyo Biologics, Inc.

AZYO•NASDAQ
Market cap
$24.21M
Sentiment

Your view on AZYO

Mkt Cap
$24.21M
Sentiment
Your view
AZYO
Aziyo Biologics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AZYO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aziyo Biologics, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
C. Randal Mills
Headquarters
US
Industry
Medical - Devices
Sector
Healthcare
CEO
C. Randal Mills
Headquarters
US
Description

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News